Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
Affiliation
Early Breast Cancer Trialists' Collaborative GroupIssue Date
1992-01-11
Metadata
Show full item recordCitation
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. 1992, 339 (8785):71-85 LancetJournal
LancetDOI
10.1016/0140-6736(92)90997-HPubMed ID
1345869Type
ArticleLanguage
enISSN
0140-6736ae974a485f413a2113503eed53cd6c53
10.1016/0140-6736(92)90997-H
Scopus Count
Collections
Related articles
- Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
- Authors: Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H, Austrian Breast and Colorectal Cancer Study Group Trial 5
- Issue date: 2002 Dec 15
- [Adjuvant therapy of breast cancer].
- Authors: Semiglazov VF, Abzumanov AS, Bozhok AA, Ivanov VG, Ivanova OA, Barash NIu, Topuzov EE, Seleznev IK, Migmanova NSh, Popova RT, Nurgaziev KSh
- Issue date: 2001